July 20 (Reuters) - Veterinarian pharmaceutical company Virbac VIRB.PA said on Monday it expected a drop in sales for the full-year 2020, amid pressure on supplies due to the coronavirus crisis and uncertainty about demand.
The French company now forecasts a decline in revenue of between -3% and 0% for the year at constant exchange rates.
The group, which makes food, shampoos and medicines for pets and farm animals, posted second-quarter sales of 230.6 million euros ($264 million), a decline of 6.4% compared to 246.1 million euros in the year-ago period.
($1 = 0.8743 euros)
(Reporting by Linda Pasquini; Editing by Edmund Blair)
((linda.pasquini@thomsonreuters.com; +48 58 7785261;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
